The impact of COVID-19 on people who inject drugs in New York City: increased risk and decreased access to services

While people who inject drugs (PWID) are vulnerable to the adverse outcomes of events like COVID-19, little is known regarding the impact of the current pandemic on PWID. We examine how COVID-19 has affected PWID in New York City across four domains: substance use, risk behaviors, mental health, and...

Full description

Saved in:
Bibliographic Details
Published inHarm reduction journal Vol. 18; no. 1; pp. 118 - 12
Main Authors Aponte-Melendez, Yesenia, Mateu-Gelabert, Pedro, Fong, Chunki, Eckhardt, Benjamin, Kapadia, Shashi, Marks, Kristen
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 24.11.2021
BioMed Central
BMC
Subjects
Alcohol use
Big events
Buprenorphine
Care and treatment
Clinical trials
Complications and side effects
Control
Coronaviruses
COVID-19
Cross-Sectional Studies
Disease transmission
Dispensing machines
Drug use
Drugs
Epidemics
Fatalities
Harm reduction
HCV
HIV Infections
Humans
Hurricanes
Informal economy
Injection
Interviews
Intravenous drug abuse
Management
Marginalized groups
Mental disorders
Mental health
New York City
New York City - epidemiology
Pandemics
People who inject drugs
Pharmaceutical Preparations
Public health
Risk
Risk taking
Sanitation
SARS-CoV-2
Social aspects
Social isolation
Substance Abuse, Intravenous - epidemiology
Substance use
Syringes
New York City
New York
United States > US
New York City New York
Big events
COVID-19
New York City
HCV
People who inject drugs
Online AccessGet full text

Cover

Abstract While people who inject drugs (PWID) are vulnerable to the adverse outcomes of events like COVID-19, little is known regarding the impact of the current pandemic on PWID. We examine how COVID-19 has affected PWID in New York City across four domains: substance use, risk behaviors, mental health, and service utilization. As part of a randomized trial to improve access to HCV treatment for PWID, we recruited 165 participants. Eligibility criteria included detectable HCV RNA and recent drug injection. The present cross-sectional analysis is based on a subsample of 106 participants. We compared responses between two separate samples: 60 participants interviewed prior to the pandemic (pre-COVID-19 sample) and 46 participants interviewed during the pandemic (COVID-19 sample). We also assessed differences by study group [accessible care (AC) and usual care (UC)]. Compared to the pre-COVID-19 sample, those interviewed during COVID-19 reported higher levels of mental health issues, syringe reuse, and alcohol consumption and greater reductions in syringe-service programs and buprenorphine utilization. In the analysis conducted by study group, the UC group reported significantly higher injection risk behaviors and lower access to buprenorphine treatment during COVID-19, while during the same period, the AC group reported lower levels of substance use and injection risk behaviors. The current study provides insight on how COVID-19 has negatively affected PWID. Placing dispensing machines of harm-reduction supplies in communities where PWID live and increasing secondary exchange, mobile services, and mail delivery of supplies may help maintain access to lifesaving supplies during big events, such as COVID-19. Trial registration ClinicalTrials.gov NCT03214679. Registered July 11 2017. https://clinicaltrials.gov/ct2/show/NCT03214679 .
AbstractList While people who inject drugs (PWID) are vulnerable to the adverse outcomes of events like COVID-19, little is known regarding the impact of the current pandemic on PWID. We examine how COVID-19 has affected PWID in New York City across four domains: substance use, risk behaviors, mental health, and service utilization.BACKGROUNDWhile people who inject drugs (PWID) are vulnerable to the adverse outcomes of events like COVID-19, little is known regarding the impact of the current pandemic on PWID. We examine how COVID-19 has affected PWID in New York City across four domains: substance use, risk behaviors, mental health, and service utilization.As part of a randomized trial to improve access to HCV treatment for PWID, we recruited 165 participants. Eligibility criteria included detectable HCV RNA and recent drug injection. The present cross-sectional analysis is based on a subsample of 106 participants. We compared responses between two separate samples: 60 participants interviewed prior to the pandemic (pre-COVID-19 sample) and 46 participants interviewed during the pandemic (COVID-19 sample). We also assessed differences by study group [accessible care (AC) and usual care (UC)].METHODSAs part of a randomized trial to improve access to HCV treatment for PWID, we recruited 165 participants. Eligibility criteria included detectable HCV RNA and recent drug injection. The present cross-sectional analysis is based on a subsample of 106 participants. We compared responses between two separate samples: 60 participants interviewed prior to the pandemic (pre-COVID-19 sample) and 46 participants interviewed during the pandemic (COVID-19 sample). We also assessed differences by study group [accessible care (AC) and usual care (UC)].Compared to the pre-COVID-19 sample, those interviewed during COVID-19 reported higher levels of mental health issues, syringe reuse, and alcohol consumption and greater reductions in syringe-service programs and buprenorphine utilization. In the analysis conducted by study group, the UC group reported significantly higher injection risk behaviors and lower access to buprenorphine treatment during COVID-19, while during the same period, the AC group reported lower levels of substance use and injection risk behaviors.RESULTSCompared to the pre-COVID-19 sample, those interviewed during COVID-19 reported higher levels of mental health issues, syringe reuse, and alcohol consumption and greater reductions in syringe-service programs and buprenorphine utilization. In the analysis conducted by study group, the UC group reported significantly higher injection risk behaviors and lower access to buprenorphine treatment during COVID-19, while during the same period, the AC group reported lower levels of substance use and injection risk behaviors.The current study provides insight on how COVID-19 has negatively affected PWID. Placing dispensing machines of harm-reduction supplies in communities where PWID live and increasing secondary exchange, mobile services, and mail delivery of supplies may help maintain access to lifesaving supplies during big events, such as COVID-19. Trial registration ClinicalTrials.gov NCT03214679. Registered July 11 2017. https://clinicaltrials.gov/ct2/show/NCT03214679 .CONCLUSIONThe current study provides insight on how COVID-19 has negatively affected PWID. Placing dispensing machines of harm-reduction supplies in communities where PWID live and increasing secondary exchange, mobile services, and mail delivery of supplies may help maintain access to lifesaving supplies during big events, such as COVID-19. Trial registration ClinicalTrials.gov NCT03214679. Registered July 11 2017. https://clinicaltrials.gov/ct2/show/NCT03214679 .
Background While people who inject drugs (PWID) are vulnerable to the adverse outcomes of events like COVID-19, little is known regarding the impact of the current pandemic on PWID. We examine how COVID-19 has affected PWID in New York City across four domains: substance use, risk behaviors, mental health, and service utilization. Methods As part of a randomized trial to improve access to HCV treatment for PWID, we recruited 165 participants. Eligibility criteria included detectable HCV RNA and recent drug injection. The present cross-sectional analysis is based on a subsample of 106 participants. We compared responses between two separate samples: 60 participants interviewed prior to the pandemic (pre-COVID-19 sample) and 46 participants interviewed during the pandemic (COVID-19 sample). We also assessed differences by study group [accessible care (AC) and usual care (UC)]. Results Compared to the pre-COVID-19 sample, those interviewed during COVID-19 reported higher levels of mental health issues, syringe reuse, and alcohol consumption and greater reductions in syringe-service programs and buprenorphine utilization. In the analysis conducted by study group, the UC group reported significantly higher injection risk behaviors and lower access to buprenorphine treatment during COVID-19, while during the same period, the AC group reported lower levels of substance use and injection risk behaviors. Conclusion The current study provides insight on how COVID-19 has negatively affected PWID. Placing dispensing machines of harm-reduction supplies in communities where PWID live and increasing secondary exchange, mobile services, and mail delivery of supplies may help maintain access to lifesaving supplies during big events, such as COVID-19. Trial registration ClinicalTrials.gov NCT03214679. Registered July 11 2017. https://clinicaltrials.gov/ct2/show/NCT03214679.
While people who inject drugs (PWID) are vulnerable to the adverse outcomes of events like COVID-19, little is known regarding the impact of the current pandemic on PWID. We examine how COVID-19 has affected PWID in New York City across four domains: substance use, risk behaviors, mental health, and service utilization. As part of a randomized trial to improve access to HCV treatment for PWID, we recruited 165 participants. Eligibility criteria included detectable HCV RNA and recent drug injection. The present cross-sectional analysis is based on a subsample of 106 participants. We compared responses between two separate samples: 60 participants interviewed prior to the pandemic (pre-COVID-19 sample) and 46 participants interviewed during the pandemic (COVID-19 sample). We also assessed differences by study group [accessible care (AC) and usual care (UC)]. Compared to the pre-COVID-19 sample, those interviewed during COVID-19 reported higher levels of mental health issues, syringe reuse, and alcohol consumption and greater reductions in syringe-service programs and buprenorphine utilization. In the analysis conducted by study group, the UC group reported significantly higher injection risk behaviors and lower access to buprenorphine treatment during COVID-19, while during the same period, the AC group reported lower levels of substance use and injection risk behaviors. The current study provides insight on how COVID-19 has negatively affected PWID. Placing dispensing machines of harm-reduction supplies in communities where PWID live and increasing secondary exchange, mobile services, and mail delivery of supplies may help maintain access to lifesaving supplies during big events, such as COVID-19. Trial registration ClinicalTrials.gov NCT03214679. Registered July 11 2017. https://clinicaltrials.gov/ct2/show/NCT03214679 .
While people who inject drugs (PWID) are vulnerable to the adverse outcomes of events like COVID-19, little is known regarding the impact of the current pandemic on PWID. We examine how COVID-19 has affected PWID in New York City across four domains: substance use, risk behaviors, mental health, and service utilization. As part of a randomized trial to improve access to HCV treatment for PWID, we recruited 165 participants. Eligibility criteria included detectable HCV RNA and recent drug injection. The present cross-sectional analysis is based on a subsample of 106 participants. We compared responses between two separate samples: 60 participants interviewed prior to the pandemic (pre-COVID-19 sample) and 46 participants interviewed during the pandemic (COVID-19 sample). We also assessed differences by study group [accessible care (AC) and usual care (UC)]. Compared to the pre-COVID-19 sample, those interviewed during COVID-19 reported higher levels of mental health issues, syringe reuse, and alcohol consumption and greater reductions in syringe-service programs and buprenorphine utilization. In the analysis conducted by study group, the UC group reported significantly higher injection risk behaviors and lower access to buprenorphine treatment during COVID-19, while during the same period, the AC group reported lower levels of substance use and injection risk behaviors. The current study provides insight on how COVID-19 has negatively affected PWID. Placing dispensing machines of harm-reduction supplies in communities where PWID live and increasing secondary exchange, mobile services, and mail delivery of supplies may help maintain access to lifesaving supplies during big events, such as COVID-19.
Abstract Background While people who inject drugs (PWID) are vulnerable to the adverse outcomes of events like COVID-19, little is known regarding the impact of the current pandemic on PWID. We examine how COVID-19 has affected PWID in New York City across four domains: substance use, risk behaviors, mental health, and service utilization. Methods As part of a randomized trial to improve access to HCV treatment for PWID, we recruited 165 participants. Eligibility criteria included detectable HCV RNA and recent drug injection. The present cross-sectional analysis is based on a subsample of 106 participants. We compared responses between two separate samples: 60 participants interviewed prior to the pandemic (pre-COVID-19 sample) and 46 participants interviewed during the pandemic (COVID-19 sample). We also assessed differences by study group [accessible care (AC) and usual care (UC)]. Results Compared to the pre-COVID-19 sample, those interviewed during COVID-19 reported higher levels of mental health issues, syringe reuse, and alcohol consumption and greater reductions in syringe-service programs and buprenorphine utilization. In the analysis conducted by study group, the UC group reported significantly higher injection risk behaviors and lower access to buprenorphine treatment during COVID-19, while during the same period, the AC group reported lower levels of substance use and injection risk behaviors. Conclusion The current study provides insight on how COVID-19 has negatively affected PWID. Placing dispensing machines of harm-reduction supplies in communities where PWID live and increasing secondary exchange, mobile services, and mail delivery of supplies may help maintain access to lifesaving supplies during big events, such as COVID-19. Trial registration ClinicalTrials.gov NCT03214679. Registered July 11 2017. https://clinicaltrials.gov/ct2/show/NCT03214679 .
Background While people who inject drugs (PWID) are vulnerable to the adverse outcomes of events like COVID-19, little is known regarding the impact of the current pandemic on PWID. We examine how COVID-19 has affected PWID in New York City across four domains: substance use, risk behaviors, mental health, and service utilization. Methods As part of a randomized trial to improve access to HCV treatment for PWID, we recruited 165 participants. Eligibility criteria included detectable HCV RNA and recent drug injection. The present cross-sectional analysis is based on a subsample of 106 participants. We compared responses between two separate samples: 60 participants interviewed prior to the pandemic (pre-COVID-19 sample) and 46 participants interviewed during the pandemic (COVID-19 sample). We also assessed differences by study group [accessible care (AC) and usual care (UC)]. Results Compared to the pre-COVID-19 sample, those interviewed during COVID-19 reported higher levels of mental health issues, syringe reuse, and alcohol consumption and greater reductions in syringe-service programs and buprenorphine utilization. In the analysis conducted by study group, the UC group reported significantly higher injection risk behaviors and lower access to buprenorphine treatment during COVID-19, while during the same period, the AC group reported lower levels of substance use and injection risk behaviors. Conclusion The current study provides insight on how COVID-19 has negatively affected PWID. Placing dispensing machines of harm-reduction supplies in communities where PWID live and increasing secondary exchange, mobile services, and mail delivery of supplies may help maintain access to lifesaving supplies during big events, such as COVID-19. Trial registration ClinicalTrials.gov NCT03214679. Registered July 11 2017. Keywords: People who inject drugs, COVID-19, HCV, New York City, Big events
ArticleNumber 118
Audience Academic
Author Aponte-Melendez, Yesenia
Mateu-Gelabert, Pedro
Kapadia, Shashi
Fong, Chunki
Eckhardt, Benjamin
Marks, Kristen
Author_xml – sequence: 1
  givenname: Yesenia
  orcidid: 0000-0003-1288-7684
  surname: Aponte-Melendez
  fullname: Aponte-Melendez, Yesenia
– sequence: 2
  givenname: Pedro
  surname: Mateu-Gelabert
  fullname: Mateu-Gelabert, Pedro
– sequence: 3
  givenname: Chunki
  surname: Fong
  fullname: Fong, Chunki
– sequence: 4
  givenname: Benjamin
  surname: Eckhardt
  fullname: Eckhardt, Benjamin
– sequence: 5
  givenname: Shashi
  surname: Kapadia
  fullname: Kapadia, Shashi
– sequence: 6
  givenname: Kristen
  surname: Marks
  fullname: Marks, Kristen
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34819070$$D View this record in MEDLINE/PubMed
BookMark eNp9kktvEzEUhUeoiD7gD7BAltiwmWKPPbbDAqkKr0gV3RQkVtaNfZ04nYxTe9Kq_x4naaGpEJqFx2e-e6zjOcfVQR97rKrXjJ4ypuX7zJpRK2rasJrSVuqaP6uOmFCqVi1TB4_eD6vjnBeUFp7rF9UhF5qNqKJHVb6cIwnLFdiBRE_GFz8nn2o2IrEnK4yrDsntPJLQL7AALq1nuWzId7wlv2K6IuMw3H0oik0IGR1JIV8R6B1x-CCBtZgzGSLJmG5C2bysnnvoMr66X0-qH18-X46_1ecXXyfjs_PatpIPNeclpRBUg-PMWw4OlEbUzrVCT4tMpRcKOGrGBFKtJfXWAQqQ2HLX8JNqsvN1ERZmlcIS0p2JEMxWiGlmIA3BdmjYtFFWMi8kRaFbr1EBE4CSjfjUKl-8Pu68VuvpEp3FfkjQ7Znuf-nD3MzijdGSMcnbYvDu3iDF6zXmwSxDtth10GNcZ9NI2kjBZbtB3z5BF3Gd-nJVhWKMl18t1V9qBiVA6H0s59qNqTkrgFCab6nTf1DlcbgMtvTJh6LvDbx5HPRPwofKFEDvAJtizgm9sWGAIcRN7tAZRs2mnWbXTlPaabbtNLyMNk9GH9z_M_Qb1gHkew
CitedBy_id crossref_primary_10_1186_s12954_023_00732_x
crossref_primary_10_1111_add_16324
crossref_primary_10_1371_journal_pone_0293238
crossref_primary_10_1080_10826084_2024_2434681
crossref_primary_10_1093_pnasnexus_pgad064
crossref_primary_10_1097_OLQ_0000000000001935
crossref_primary_10_1111_dar_13456
crossref_primary_10_1007_s10461_022_03851_x
crossref_primary_10_1377_hlthaff_2024_00032
crossref_primary_10_1016_j_dadr_2023_100141
crossref_primary_10_1093_infdis_jiae599
crossref_primary_10_1186_s12954_022_00622_8
crossref_primary_10_1097_ADM_0000000000001036
crossref_primary_10_1016_j_drugalcdep_2023_109802
crossref_primary_10_1186_s12954_023_00791_0
crossref_primary_10_1016_j_dld_2022_07_007
crossref_primary_10_1016_j_japh_2022_10_018
crossref_primary_10_1016_j_drugpo_2024_104356
crossref_primary_10_1016_j_drugpo_2024_104452
crossref_primary_10_1186_s12954_022_00715_4
crossref_primary_10_1016_j_drugpo_2023_104073
crossref_primary_10_1080_09581596_2023_2250908
crossref_primary_10_1093_eurpub_ckad156
crossref_primary_10_1186_s12954_022_00721_6
crossref_primary_10_1097_QAD_0000000000004076
crossref_primary_10_1186_s12954_023_00742_9
crossref_primary_10_1186_s12954_023_00746_5
crossref_primary_10_3390_v16050655
crossref_primary_10_1136_bmjopen_2024_086141
crossref_primary_10_1186_s12954_022_00660_2
crossref_primary_10_3390_ijerph19063459
crossref_primary_10_1186_s12954_023_00804_y
crossref_primary_10_1016_j_dadr_2023_100154
crossref_primary_10_7759_cureus_39023
crossref_primary_10_3390_ijerph20021295
crossref_primary_10_1016_j_jmh_2024_100267
crossref_primary_10_1371_journal_pone_0308102
crossref_primary_10_1093_abm_kaad012
crossref_primary_10_1186_s12954_022_00631_7
crossref_primary_10_1016_j_drugpo_2025_104746
crossref_primary_10_1186_s12954_024_01008_8
crossref_primary_10_1007_s10461_022_03899_9
crossref_primary_10_1186_s12889_023_15933_z
crossref_primary_10_1002_jia2_26036
crossref_primary_10_1007_s10461_025_04615_z
Cites_doi 10.1007/s10461-020-03141-4
10.1016/j.drugpo.2015.05.003
10.1007/s11524-014-9904-5
10.1080/00952990500479522
10.1080/10714839.2020.1809078
10.1371/journal.pone.0236337
10.1016/j.drugpo.2021.103127
10.1186/s12954-020-00445-5
10.1016/j.jsat.2021.108514
10.1037/tra0000660
10.1016/j.drugpo.2020.102905
10.1016/j.drugpo.2021.103391
10.2471/BLT.06.033019
10.1097/ADM.0000000000000685
10.1080/08897077.2021.1986768
10.1016/j.jadohealth.2020.06.018
10.1016/j.dsx.2020.06.008
10.3389/fpsyt.2020.00714
10.1186/s12954-021-00472-w
10.1186/1471-2458-8-92
10.1097/ADM.0000000000000684
10.1016/j.drugalcdep.2021.108589
10.1016/j.drugpo.2014.11.007
10.1111/bjhp.12485
10.1016/0740-5472(92)90062-S
10.1016/j.drugpo.2020.102958
10.1016/S2468-2667(21)00013-X
10.1016/j.drugpo.2021.103199
10.1016/j.drugpo.2020.102903
10.1186/1751-0473-3-17
10.1016/j.jsat.2021.108276
10.15585/mmwr.mm7013e2
10.1016/j.drugpo.2011.08.005
10.1002/jia2.25583
10.1186/s12954-020-00432-w
10.3390/ijerph18168470
10.1007/s10461-020-02886-2
10.1186/s13034-020-00329-3
10.1016/j.drugalcdep.2010.09.011
10.1186/s12939-020-01242-z
10.1016/j.drugpo.2020.102851
10.1016/j.drugpo.2008.10.006
10.3109/10826084.2015.978675
10.1186/s12954-020-00370-7
10.1038/s41380-020-00880-7
10.1016/j.jsat.2020.108181
ContentType Journal Article
Copyright 2021. The Author(s).
COPYRIGHT 2021 BioMed Central Ltd.
2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2021
Copyright_xml – notice: 2021. The Author(s).
– notice: COPYRIGHT 2021 BioMed Central Ltd.
– notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2021
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
ATCPS
AZQEC
BENPR
BHPHI
CCPQU
COVID
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
M0S
M1P
PATMY
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
PYCSY
7X8
5PM
DOA
DOI 10.1186/s12954-021-00568-3
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
Agricultural & Environmental Science Collection
ProQuest Central Essentials
ProQuest Central
Natural Science Collection
ProQuest One Community College
Coronavirus Research Database
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
Environmental Science Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Environmental Science Collection
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Agricultural & Environmental Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Environmental Science Collection
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Environmental Science Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
Publicly Available Content Database
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Social Welfare & Social Work
Public Health
EISSN 1477-7517
EndPage 12
ExternalDocumentID oai_doaj_org_article_1b27c61f460e485f8e7a14ae6193bc7f
PMC8611635
A686478367
34819070
10_1186_s12954_021_00568_3
Genre Randomized Controlled Trial
Journal Article
Research Support, N.I.H., Extramural
GeographicLocations New York City
New York
United States--US
New York City New York
GeographicLocations_xml – name: New York City
– name: New York
– name: New York City New York
– name: United States--US
GrantInformation_xml – fundername: NIDA NIH HHS
  grantid: K01DA048172
– fundername: NIDA NIH HHS
  grantid: R01DA041298
– fundername: NIDA NIH HHS
  grantid: K01 DA048172
– fundername: NIDA NIH HHS
  grantid: T32 DA007233
– fundername: ;
  grantid: R01DA041298; R01DA041298; K01DA048172; T32 DA007233
GroupedDBID ---
0R~
29I
2WC
2XV
53G
5GY
5VS
7X7
7XC
88E
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABIVO
ABUWG
ACGFO
ACGFS
ACHQT
ACIHN
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AEUYN
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
ATCPS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BHPHI
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
IAO
IHR
INH
INR
IPY
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PATMY
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
PYCSY
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
3V.
7XB
8FK
AZQEC
COVID
DWQXO
GNUQQ
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c563t-331184408ad31fc3ada78ee8dd548b08a06f47a3e8114e08860fcdae4a6e53d23
IEDL.DBID M48
ISSN 1477-7517
IngestDate Wed Aug 27 01:09:34 EDT 2025
Thu Aug 21 18:18:40 EDT 2025
Fri Jul 11 12:08:29 EDT 2025
Fri Jul 25 22:29:42 EDT 2025
Tue Jun 17 21:28:37 EDT 2025
Tue Jun 10 20:45:37 EDT 2025
Thu Apr 03 07:03:58 EDT 2025
Tue Jul 01 00:46:58 EDT 2025
Thu Apr 24 23:01:25 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Big events
COVID-19
New York City
HCV
People who inject drugs
Language English
License 2021. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c563t-331184408ad31fc3ada78ee8dd548b08a06f47a3e8114e08860fcdae4a6e53d23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ORCID 0000-0003-1288-7684
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12954-021-00568-3
PMID 34819070
PQID 2611356867
PQPubID 105462
PageCount 12
ParticipantIDs doaj_primary_oai_doaj_org_article_1b27c61f460e485f8e7a14ae6193bc7f
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8611635
proquest_miscellaneous_2602643655
proquest_journals_2611356867
gale_infotracmisc_A686478367
gale_infotracacademiconefile_A686478367
pubmed_primary_34819070
crossref_citationtrail_10_1186_s12954_021_00568_3
crossref_primary_10_1186_s12954_021_00568_3
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-11-24
PublicationDateYYYYMMDD 2021-11-24
PublicationDate_xml – month: 11
  year: 2021
  text: 2021-11-24
  day: 24
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Harm reduction journal
PublicationTitleAlternate Harm Reduct J
PublicationYear 2021
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References V Saladino (568_CR4) 2020; 2
568_CR37
PC Treitler (568_CR45) 2022; 132
A Seaman (568_CR61) 2021; 25
ER Pouget (568_CR34) 2015; 50
568_CR2
TM Dumas (568_CR7) 2020; 67
568_CR1
C Fong (568_CR21) 2021; 221
T Parkes (568_CR30) 2021; 18
568_CR31
R Wilkinson (568_CR60) 2020; 17
568_CR6
568_CR5
A Dunlop (568_CR8) 2020; 17
JM Fegert (568_CR49) 2020; 14
B McClure (568_CR41) 2014; 91
CA Picchio (568_CR26) 2020; 17
AT McLellan (568_CR38) 1992; 9
BF Henry (568_CR51) 2020; 12
R Abadie (568_CR16) 2021; 93
M Cerdá (568_CR56) 2011; 115
E Durkheim (568_CR52) 1951
JM Kesten (568_CR25) 2021; 98
M Alavi (568_CR40) 2015; 26
J Grebely (568_CR15) 2020; 83
SN Glick (568_CR9) 2020; 24
WB Jemberie (568_CR20) 2020; 11
RC Kessler (568_CR57) 2006; 84
568_CR43
568_CR44
Y Rozenfeld (568_CR3) 2020; 19
SR Friedman (568_CR33) 2009; 20
S Vetter (568_CR36) 2008; 8
568_CR12
568_CR13
M Whitfield (568_CR29) 2020; 83
TI Vasylyeva (568_CR17) 2020; 23
Z Bursac (568_CR39) 2008; 3
CS Davis (568_CR46) 2021; 93
DP Wilson (568_CR54) 2015; 26
MM Islam (568_CR19) 2012; 23
EA Samuels (568_CR47) 2020; 14
MJ Dubey (568_CR11) 2020; 14
C Zolopa (568_CR35) 2021; 92
C Gelpí-Acosta (568_CR32) 2020; 52
MC Figgatt (568_CR42) 2021; 123
C Arum (568_CR18) 2021; 6
RE Adams (568_CR55) 2006; 32
JP Nithke (568_CR58) 2021; 26
A Vahratian (568_CR50) 2021; 70
R Tringale (568_CR63) 2021; 121
568_CR23
568_CR24
UG Khatri (568_CR10) 2020; 14
568_CR27
B Hay (568_CR53) 2017; 7
QQ Wang (568_CR14) 2021; 26
568_CR22
A Munro (568_CR28) 2021; 18
SR Radfar (568_CR59) 2021; 29
R French (568_CR62) 2021; 94
T Elmer (568_CR48) 2020; 15
References_xml – volume: 25
  start-page: 1331
  issue: 5
  year: 2021
  ident: 568_CR61
  publication-title: AIDS Behav
  doi: 10.1007/s10461-020-03141-4
– ident: 568_CR27
– ident: 568_CR23
– volume: 26
  start-page: 976
  issue: 10
  year: 2015
  ident: 568_CR40
  publication-title: Int J Drug Policy
  doi: 10.1016/j.drugpo.2015.05.003
– ident: 568_CR13
– volume: 7
  start-page: 211
  year: 2017
  ident: 568_CR53
  publication-title: Front Psych
– volume: 91
  start-page: 999
  issue: 5
  year: 2014
  ident: 568_CR41
  publication-title: J Urban Health
  doi: 10.1007/s11524-014-9904-5
– volume: 32
  start-page: 203
  issue: 2
  year: 2006
  ident: 568_CR55
  publication-title: Am J Drug Alcohol Abuse
  doi: 10.1080/00952990500479522
– ident: 568_CR24
– volume: 52
  start-page: 252
  issue: 3
  year: 2020
  ident: 568_CR32
  publication-title: NACLA Rep Am
  doi: 10.1080/10714839.2020.1809078
– volume: 15
  start-page: e0236337
  issue: 7
  year: 2020
  ident: 568_CR48
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0236337
– volume: 92
  start-page: 103127
  year: 2021
  ident: 568_CR35
  publication-title: Int J Drug Policy
  doi: 10.1016/j.drugpo.2021.103127
– ident: 568_CR1
– volume: 17
  start-page: 1
  issue: 1
  year: 2020
  ident: 568_CR60
  publication-title: Harm Reduct J
  doi: 10.1186/s12954-020-00445-5
– volume: 132
  start-page: 108514
  year: 2022
  ident: 568_CR45
  publication-title: J Subst Abuse Treat
  doi: 10.1016/j.jsat.2021.108514
– volume: 12
  start-page: S111
  issue: S1
  year: 2020
  ident: 568_CR51
  publication-title: Psychol Trauma Theory Res Pract Policy
  doi: 10.1037/tra0000660
– ident: 568_CR5
– volume: 93
  start-page: 102905
  year: 2021
  ident: 568_CR46
  publication-title: Int J Drug Policy
  doi: 10.1016/j.drugpo.2020.102905
– volume: 98
  start-page: 103391
  year: 2021
  ident: 568_CR25
  publication-title: Int J Drug Policy
  doi: 10.1016/j.drugpo.2021.103391
– volume: 84
  start-page: 930
  year: 2006
  ident: 568_CR57
  publication-title: Bull World Health Organ
  doi: 10.2471/BLT.06.033019
– volume: 14
  start-page: e8
  year: 2020
  ident: 568_CR47
  publication-title: J Addict Med
  doi: 10.1097/ADM.0000000000000685
– ident: 568_CR31
– ident: 568_CR44
  doi: 10.1080/08897077.2021.1986768
– volume: 67
  start-page: 354
  issue: 3
  year: 2020
  ident: 568_CR7
  publication-title: J Adolesc Health
  doi: 10.1016/j.jadohealth.2020.06.018
– volume: 14
  start-page: 817
  issue: 5
  year: 2020
  ident: 568_CR11
  publication-title: Diabetes Metab Syndr
  doi: 10.1016/j.dsx.2020.06.008
– volume: 11
  start-page: 714
  year: 2020
  ident: 568_CR20
  publication-title: Front Psychiatry
  doi: 10.3389/fpsyt.2020.00714
– volume: 18
  start-page: 1
  issue: 1
  year: 2021
  ident: 568_CR30
  publication-title: Harm Reduct J
  doi: 10.1186/s12954-021-00472-w
– volume: 8
  start-page: 1
  issue: 1
  year: 2008
  ident: 568_CR36
  publication-title: BMC Public Health
  doi: 10.1186/1471-2458-8-92
– ident: 568_CR2
– volume: 14
  start-page: e6
  year: 2020
  ident: 568_CR10
  publication-title: J Addict Med
  doi: 10.1097/ADM.0000000000000684
– volume: 221
  start-page: 108589
  year: 2021
  ident: 568_CR21
  publication-title: Drug and Alcohol Depend
  doi: 10.1016/j.drugalcdep.2021.108589
– volume: 26
  start-page: S5
  year: 2015
  ident: 568_CR54
  publication-title: Int J Drug Policy
  doi: 10.1016/j.drugpo.2014.11.007
– volume: 26
  start-page: 553
  issue: 2
  year: 2021
  ident: 568_CR58
  publication-title: Br J Health Psychol
  doi: 10.1111/bjhp.12485
– volume: 9
  start-page: 199
  issue: 3
  year: 1992
  ident: 568_CR38
  publication-title: J Subst Abuse Treat
  doi: 10.1016/0740-5472(92)90062-S
– volume: 83
  start-page: 102958
  year: 2020
  ident: 568_CR15
  publication-title: Int J Drug Policy
  doi: 10.1016/j.drugpo.2020.102958
– ident: 568_CR6
– volume: 6
  start-page: e309
  year: 2021
  ident: 568_CR18
  publication-title: Lancet Public Health.
  doi: 10.1016/S2468-2667(21)00013-X
– volume: 94
  start-page: 103199
  year: 2021
  ident: 568_CR62
  publication-title: Int J Drug Policy
  doi: 10.1016/j.drugpo.2021.103199
– volume: 93
  start-page: 102903
  year: 2021
  ident: 568_CR16
  publication-title: Int J Drug Policy
  doi: 10.1016/j.drugpo.2020.102903
– volume: 3
  start-page: 17
  issue: 1
  year: 2008
  ident: 568_CR39
  publication-title: Source Code Biol Med
  doi: 10.1186/1751-0473-3-17
– volume: 123
  start-page: 108276
  year: 2021
  ident: 568_CR42
  publication-title: J Subst Abuse Treat
  doi: 10.1016/j.jsat.2021.108276
– volume: 70
  start-page: 490
  issue: 13
  year: 2021
  ident: 568_CR50
  publication-title: Morb Mortal Wkly Rep
  doi: 10.15585/mmwr.mm7013e2
– volume: 23
  start-page: 94
  issue: 2
  year: 2012
  ident: 568_CR19
  publication-title: Int J Drug Policy
  doi: 10.1016/j.drugpo.2011.08.005
– ident: 568_CR22
– volume-title: Suicide: a study in sociology
  year: 1951
  ident: 568_CR52
– volume: 23
  start-page: e25583
  issue: 7
  year: 2020
  ident: 568_CR17
  publication-title: J Int AIDS Soc
  doi: 10.1002/jia2.25583
– volume: 17
  start-page: 87
  issue: 1
  year: 2020
  ident: 568_CR26
  publication-title: Harm Reduct J
  doi: 10.1186/s12954-020-00432-w
– volume: 18
  start-page: 8470
  issue: 16
  year: 2021
  ident: 568_CR28
  publication-title: Int J Environ Res Public Health
  doi: 10.3390/ijerph18168470
– volume: 29
  start-page: 349
  issue: 12
  year: 2021
  ident: 568_CR59
  publication-title: Front Psych
– volume: 24
  start-page: 2466
  issue: 9
  year: 2020
  ident: 568_CR9
  publication-title: AIDS Behav
  doi: 10.1007/s10461-020-02886-2
– volume: 14
  start-page: 1
  year: 2020
  ident: 568_CR49
  publication-title: Child Adolesc Psychiatry Ment Health
  doi: 10.1186/s13034-020-00329-3
– volume: 115
  start-page: 1
  issue: 1–2
  year: 2011
  ident: 568_CR56
  publication-title: Drug Alcohol Depend
  doi: 10.1016/j.drugalcdep.2010.09.011
– volume: 19
  start-page: 1
  issue: 1
  year: 2020
  ident: 568_CR3
  publication-title: Int J Equity Health
  doi: 10.1186/s12939-020-01242-z
– ident: 568_CR37
– volume: 83
  start-page: 102851
  year: 2020
  ident: 568_CR29
  publication-title: Int J Drug Policy
  doi: 10.1016/j.drugpo.2020.102851
– volume: 20
  start-page: 283
  issue: 3
  year: 2009
  ident: 568_CR33
  publication-title: Int J Drug Policy
  doi: 10.1016/j.drugpo.2008.10.006
– volume: 2
  start-page: 2550
  issue: 11
  year: 2020
  ident: 568_CR4
  publication-title: Front Psychol
– ident: 568_CR12
– volume: 50
  start-page: 878
  issue: 7
  year: 2015
  ident: 568_CR34
  publication-title: Subst Use Misuse
  doi: 10.3109/10826084.2015.978675
– volume: 17
  start-page: 1
  issue: 1
  year: 2020
  ident: 568_CR8
  publication-title: Harm Reduct J
  doi: 10.1186/s12954-020-00370-7
– volume: 26
  start-page: 30
  issue: 1
  year: 2021
  ident: 568_CR14
  publication-title: Mol Psychiatry
  doi: 10.1038/s41380-020-00880-7
– ident: 568_CR43
– volume: 121
  start-page: 108181
  year: 2021
  ident: 568_CR63
  publication-title: J Subst Abuse Treat
  doi: 10.1016/j.jsat.2020.108181
SSID ssj0029538
Score 2.4743717
Snippet While people who inject drugs (PWID) are vulnerable to the adverse outcomes of events like COVID-19, little is known regarding the impact of the current...
Background While people who inject drugs (PWID) are vulnerable to the adverse outcomes of events like COVID-19, little is known regarding the impact of the...
Abstract Background While people who inject drugs (PWID) are vulnerable to the adverse outcomes of events like COVID-19, little is known regarding the impact...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 118
SubjectTerms Alcohol use
Big events
Buprenorphine
Care and treatment
Clinical trials
Complications and side effects
Control
Coronaviruses
COVID-19
Cross-Sectional Studies
Disease transmission
Dispensing machines
Drug use
Drugs
Epidemics
Fatalities
Harm reduction
HCV
HIV Infections
Humans
Hurricanes
Informal economy
Injection
Interviews
Intravenous drug abuse
Management
Marginalized groups
Mental disorders
Mental health
New York City
New York City - epidemiology
Pandemics
People who inject drugs
Pharmaceutical Preparations
Public health
Risk
Risk taking
Sanitation
SARS-CoV-2
Social aspects
Social isolation
Substance Abuse, Intravenous - epidemiology
Substance use
Syringes
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR1Nb9Mw1EI7cUEwvgIFPSQEB2Stjh3H4TYK00ACLgx2sxzbYdOmBDWt9vd5L06qRkhw4djnZ9X2-27fB2MvRY5E98FznYeGq9oV3HgtOLJKVdZBx2qocv38RZ-eqU_nxfneqC_KCUvtgdPDHYk6L3Fzo_QyKlM0JpZOKBfR8Ze1LxvSvmjzpmBqDLUqlOOpRMboo17Q31mc0hGo96XhcmaGhm79f-rkPaM0T5jcs0And9md0XWE43Tke-xWbA_ZItXXwo943bh1hFcwAbr11X3WIxtAqoSEroHV1-8f33NRQddCyh2Hm4sOLlv6NQbCevuzxw-Amg-olxOs0Ed_ixByLfsYgBLRwbUBQpxAbpi4CJsO-lHtPGBnJx--rU75OGeB-0LLDZcSH4kmT7sgReOlC640MZoQMJypEbzUjSqdjAaDp4hqSS8bH1xUTsdChlw-ZAdt18bHDEwR1dIZoyo0ewqjKVUjTtQBaeVr4TImpme3fmxCTrMwru0QjBhtE6ksksoOpLIyY292e36lFhx_xX5H1NxhUvvsAYBMZUemsv9iqoy9Jl6wJOR4PO_GWgW8JLXLssfaUI2u1GXGFjNMFE4_X564yY7KobcYtAqJh6XlF7tl2kkJb23stoSDwbGSuigy9igx3-5KVDtdoarOWDljy9md5yvt5cXQOtzgV6OL-eR_PNJTdjsniRKC52rBDjbrbXyGHtqmfj4I42_tJTV5
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagXJAQgvJKu6BBQnBAVtex4zhcUFmoChJwobA3y7GdtqJKymZX_H1m8tg2Qupxx47WznwznnHmwdgrkSLTffBcp6HiqnQZN14LjlAp8jLoWHRZrl-_6eMT9WWZLYcLt3YIqxx1YqeoQ-PpjvwALX0hM210_v7yD6euUfR1dWihcZvdodJlhOp8eeVwFSjNY6KM0QetoI9anIISqAKm4XJyGHU1-__XzNeOpmnY5LVz6OgBuz8YkHDYc_whuxXrXXavv32DPqlol836rFv4FS8qt4rwGkZCs_r9iLUIDujzI6GpYPH95-ePXBTQ1NBHlMPfswbOa7qjgbDanLb4A1AfAlV4ggVa7u-QQgZnGwNQeDq4OkCII8l1fRhh3UA7KKPH7OTo04_FMR-6L3CfabnmUuJLo37ULkhReemCy02MJgR0ckokz3WlciejQZcqorLS88oHF5XTMZMhlU_YTt3U8RkDk0U1d8aoAg9DhT6WKnFO1EGW3pfCJUyMbLB-KE1OHTIubOeiGG171llkne1YZ2XC3m6fuewLc9w4-wNxdzuTimp3hGZ1agcZtaJMc8RppfQ8KpNVJuZOKBfRx8SF5lXC3hA2LIk-Ls-7IYMBN0lFtOwholNRVkyesNlkJoqsnw6P6LKDymjtFcAT9nI7TE9SGFwdmw3NQZdZSZ1lCXvag3G7JcqoLlCBJyyfwHSy5-lIfX7WFRQ3-NdoeO7dvKx9djcl2RGCp2rGdtarTXyOFtm6fNGJ3T9oLzHW
  priority: 102
  providerName: ProQuest
Title The impact of COVID-19 on people who inject drugs in New York City: increased risk and decreased access to services
URI https://www.ncbi.nlm.nih.gov/pubmed/34819070
https://www.proquest.com/docview/2611356867
https://www.proquest.com/docview/2602643655
https://pubmed.ncbi.nlm.nih.gov/PMC8611635
https://doaj.org/article/1b27c61f460e485f8e7a14ae6193bc7f
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjR3bbtMw1NrlhRfEnUCpjITgARnq2LFdJIS6smlU2kBAoW-WEzvbRJVA0wr4e87JpVrEhHiqYp80ts89ORdCnvAYkJ75jKnY50ymLmEmU5wBqYx16lUY11muJ6fqeC5ni2SxQ7p2R-0BVle6dthPar5avvj14_cbYPjXNcMb9bLi-LGKYbABVrY0TOySfdBMGjsanMjtVwWAqjtbc6k10wnXXRLNlf_RU1R1Pf-_pfYltdUPqbyko45ukOutcUknDTXcJDuhuEUGTQYu_RqWuVsF-pR2A-Xq221SAaHQJleSljmdvv_y7i3jY1oWtIkupz_PS3pR4Psa6lebswouKMhGitWe6BSs-FcwgsZnFTzFUHXqCk996IZc3ZORrktatYLpDpkfHX6eHrO2EwPLEiXWTAg4JOxN7bzgeSacd9qEYLwHhyeF4ZHKpXYiGHCvAgguNcoz74J0KiTCx-Iu2SvKItwn1CRBjpwxcgyKUYK_JVOACcqLNMtS7iLCu2O3WVumHLtlLG3trhhlG1RZQJWtUWVFRJ5v7_neFOn4J_QBYnMLiQW264FydWZbfrU8jTXQbC7VKEiT5CZox6UL4G_CQnUekWdICxYJE5aXuTabATaJBbXsRBnM4hVKR2TQgwT2zfrTHTXZjvotuLVcwGJx-vF2Gu_EkLgilBuEAfdZCpUkEbnXEN92S5hdPQZhHhHdI8venvszxcV5XVzcwKPBCH3wH899SK7FyDCcs1gOyN56tQmPwERbp0Oyqxd6SPYnk9mnGfweHJ5--DisX3gMa578A6d4OPA
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3JbtQw1KrKASSEoGyBAYzEckBWx7HjeJAQKi3VDF24tDA317GdtqJKymRGFT_FN_JelmkjpN56zPOLYuvtzlsIecNjILrzjqnY50xmNmHaKc6AVUZp5lUY1VWue_tqfCi_TZPpCvnb1cJgWmWnE2tF7UuHd-Tr4OlzkSit0s_nvxlOjcK_q90IjYYtdsKfCwjZqk-TLaDv2zje_nqwOWbtVAHmEiXmTAjwqXHOsvWC505Yb1MdgvYenPcMwEOVy9SKoCFUCCCEapg7b4O0KiTCY6MDUPm3wPAOMdhLp5cB3gi0R1eYo9V6xfEnGsMkCOy4qZnoGb96RsD_luCKKeynaV6xe9v3yb3WYaUbDYc9ICuhWCN3m9s-2hQxrZFBU-VLf4az3M4CfUc7QDn79ZBUwIy0qcekZU43v_-YbDE-omVBmwx2enFS0tMC74Sony2OK3igoH8pdpSimxApfAQIOrhV8BTT4aktPPWhA9l67iOdl7Rqld8jcngjdHlMVouyCE8J1UmQQ6u1HIHxlRDTyQxwgvIicy7jNiK8I4NxbSt0nMhxZuqQSCvTkM4A6UxNOiMi8mH5znnTCORa7C9I3SUmNvGuAeXs2LQ6wfAsTkEucqmGQeok1yG1XNoAMS1sNM0j8h55w6Cqge0521ZMwCGxaZfZAGmQWIWTRmTQwwQV4frLHXeZVkVV5lKgIvJ6uYxvYtpdEcoF4kCILoVKkog8aZhxeSSs4B6BwYhI2mPT3pn7K8XpSd3AXMOnwdF9dv22XpHb44O9XbM72d95Tu7EKEecs1gOyOp8tggvwBucZy9rEaTk6KZl_h-9Qm7D
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+impact+of+COVID-19+on+people+who+inject+drugs+in+New+York+City%3A+increased+risk+and+decreased+access+to+services&rft.jtitle=Harm+reduction+journal&rft.au=Aponte-Melendez%2C+Yesenia&rft.au=Mateu-Gelabert%2C+Pedro&rft.au=Fong%2C+Chunki&rft.au=Eckhardt%2C+Benjamin&rft.date=2021-11-24&rft.issn=1477-7517&rft.eissn=1477-7517&rft.volume=18&rft.issue=1&rft.spage=118&rft_id=info:doi/10.1186%2Fs12954-021-00568-3&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-7517&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-7517&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-7517&client=summon